Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium

Leuridan, Elke; Maertens, Kirsten; Wautier, Magali; Hutse, Veronik; Theeten, Heidi

doi:10.1007/s00431-014-2481-5

Cited by 9 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The WHO advocates giving the second dose one month after the first one [11]. In Belgium, the timing for the second dose is historical and linked to the rubella/mumps vaccine for which the programme already existed and was well incorporated in the routine vaccination schedule [17]. …”

Section: Discussionmentioning

confidence: 99%

Different measles outbreaks in Belgium, January to June 2016 – a challenge for public health

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Different measles outbreaks in Belgium, January to June 2016 – a challenge for public health

et al. 2016

View full text Add to dashboard Cite

show abstract

“…These findings may be interpreted as more exposure between boys, especially face-to-face contact with high exposure, and exposures overcome vaccineinduced protection. [17][18][19][20][21] Furthermore, the seroprevalence and GMCs among children aged 2 to 3 years in the northern region were lower than those among children in the southern and central regions. The reasons may be complex, such as the economic level of the region, MuV coverage, and different contact rates.…”

Section: Discussionmentioning

confidence: 95%

High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China

Sun

Tang

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background: During the period of immunization with a single-dose measles-mumps-rubella (MMR) vaccine, which has been available since 2008in China, the incidence of mumps in children aged 2-5 years has been high. The aim of this study was to determine the immunity profile of mumps in children aged 2-5 years as part of the assessment of the MMR vaccination strategy. Methods: A cross-sectional survey of IgG antibodies against mumps virus in children aged 2-5 years was performed. Analysis by enzyme-linked immune sorbent assay(ELISA)was performed to measure IgG antibodies against mumps virus in the sera of 2-to5-year-old children who had been vaccinated with at least one dose of MMR vaccine. Results: Mumps outbreaks mainly occurred in kindergarten and primary schools and primarily involved children in kindergarten from 2015-2016 in Jiangsu Province. In total, 4,033 children were surveyed. The overall seroprevalence of mumps antibodies was 79.0% (95% CI:78.4-79.6), and the geometric mean concentration (GMC) was 323.6 mIU/ml (309.0-338.8). Both univariate and multivariate survival analysis of seroprevalence showed that several factors contributed to having significant seroprevalence among the 2-to-5-year-old group (P < .05). The seroprevalence of children with a single-dose MMR vaccine regimen (78.4%, 95% CI: 77.8-80.4) was significantly lower than that of children with a two-dose MMR vaccine regimen (96.5%, 95% CI: 88.6%-96.1%). The seroprevalence rate was negatively correlated with time since inoculation (P < .01). Conclusion:Children who received a single dose of MMR vaccine in kindergarten, particularly the 2-year-old group in the northern region of Jiangsu Province, China, are at high risk of mumps infection. Our study demonstrates thata single-dose MMR vaccine regimen has a limited effect on controlling mumps, which highlights the benefit of introducing a two-dose MMR vaccine schedule.

show abstract

“…Thirdly, numerous ELISA kits are commercially available and have been used in previous studies investigating anti-mumps IgG seroprevalence [3–6, 13]. However, the cutoff value for anti-mumps IgG levels measured using these kits is not standardized.…”

Section: Limitationsmentioning

confidence: 99%

“…However, the cutoff value for anti-mumps IgG levels measured using these kits is not standardized. In the present study, we followed the manufacturer’s instructions to determine the IgG levels as positive, but other studies used different quantitative ELISA values with the same Enzygnost ® ELISA kit (Siemens Healthcare Diagnostics) [6]. Therefore, direct comparison of age-specific mumps IgG seroprevalence is not conclusive.…”

Section: Limitationsmentioning

confidence: 99%

“…In total, 122 countries have introduced one of the mumps-containing vaccines nationwide as of 2017 [2]. Although many studies have investigated the seroprevalence of anti-mumps antibody, most recent studies were conducted after the introduction of the mumps-containing vaccine nationwide [3–6]. The majority of studies on anti-mumps antibody seroprevalence in the pre-vaccination era were conducted either in European countries before 1990 [7–10] or outside Europe [11–13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Seroprevalence of mumps before the introduction of mumps-containing vaccine in Lao PDR: results from a nationwide cross-sectional population-based survey

et al. 2019

View full text Add to dashboard Cite

ObjectiveMumps-containing vaccine is currently not a component of the national immunization schedule in Lao People’s Democratic Republic (PDR). Mumps itself is not a notifiable disease in the country and the seroprevalence of anti-mumps immunoglobulin G (IgG) in the general population is unknown. In this study, anti-mumps IgG was measured in 2058 blood samples to evaluate population immunity in the country.ResultsThe seroprevalence of anti-mumps IgG showed a gradual increase with increasing age, starting at 10.6% (95% CI 7.4–13.7) in participants aged 1–2 years, and almost plateaued at about 75% in individuals older than 11–12 years, though it still tended toward a small increase up to 89.6% (95% CI 86.6–92.6) in participants aged 40 years or older. Compared with the results of previous studies, this increase with increasing age is less marked and the plateau of anti-mumps seroprevalence is lower. We attribute this result mainly to the lower population density in Lao PDR.

show abstract

Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium

Abstract: The data show considerable susceptibility to mumps and measles in 5-year-old children, confirming a previously conducted seroprevalence study (2006). Both advantages and disadvantages of shortening or enlarging the vaccine schedule are discussed.

Cited by 9 publications

References 33 publications

Different measles outbreaks in Belgium, January to June 2016 – a challenge for public health

Different measles outbreaks in Belgium, January to June 2016 – a challenge for public health

High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China

Seroprevalence of mumps before the introduction of mumps-containing vaccine in Lao PDR: results from a nationwide cross-sectional population-based survey

Contact Info

Product

Resources

About